ENTRADA THERAPEUTICS INC (TRDA) Fundamental Analysis & Valuation

NASDAQ:TRDA • US29384C1080

Current stock price

13.15 USD
-0.33 (-2.45%)
At close:
13.15 USD
0 (0%)
After Hours:

This TRDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TRDA Profitability Analysis

1.1 Basic Checks

  • TRDA had negative earnings in the past year.
  • In the past year TRDA has reported a negative cash flow from operations.
  • In the past 5 years TRDA reported 4 times negative net income.
  • In the past 5 years TRDA reported 4 times negative operating cash flow.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -38.09%, TRDA is in line with its industry, outperforming 57.64% of the companies in the same industry.
  • TRDA has a Return On Equity of -46.96%. This is in the better half of the industry: TRDA outperforms 65.76% of its industry peers.
Industry RankSector Rank
ROA -38.09%
ROE -46.96%
ROIC N/A
ROA(3y)-9.02%
ROA(5y)-16.26%
ROE(3y)-11.47%
ROE(5y)-19.21%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TRDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TRDA Health Analysis

2.1 Basic Checks

  • TRDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TRDA has more shares outstanding than it did 1 year ago.
  • TRDA has more shares outstanding than it did 5 years ago.
  • TRDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 2.81 indicates that TRDA is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.81, TRDA is doing good in the industry, outperforming 66.92% of the companies in the same industry.
  • There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.81
ROIC/WACCN/A
WACC9.2%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 12.53 indicates that TRDA has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 12.53, TRDA belongs to the top of the industry, outperforming 86.46% of the companies in the same industry.
  • A Quick Ratio of 12.53 indicates that TRDA has no problem at all paying its short term obligations.
  • The Quick ratio of TRDA (12.53) is better than 86.46% of its industry peers.
Industry RankSector Rank
Current Ratio 12.53
Quick Ratio 12.53
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TRDA Growth Analysis

3.1 Past

  • The earnings per share for TRDA have decreased strongly by -281.15% in the last year.
  • Looking at the last year, TRDA shows a very negative growth in Revenue. The Revenue has decreased by -87.94% in the last year.
EPS 1Y (TTM)-281.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3233.33%
Revenue 1Y (TTM)-87.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-96.53%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.49% on average over the next years.
  • Based on estimates for the next years, TRDA will show a very strong growth in Revenue. The Revenue will grow by 46.56% on average per year.
EPS Next Y-14.21%
EPS Next 2Y-5.45%
EPS Next 3Y-0.93%
EPS Next 5Y6.49%
Revenue Next Year14.56%
Revenue Next 2Y31.43%
Revenue Next 3Y29.85%
Revenue Next 5Y46.56%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. TRDA Valuation Analysis

4.1 Price/Earnings Ratio

  • TRDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TRDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.45%
EPS Next 3Y-0.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TRDA Dividend Analysis

5.1 Amount

  • No dividends for TRDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRDA Fundamentals: All Metrics, Ratios and Statistics

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (4/2/2026, 8:00:01 PM)

After market: 13.15 0 (0%)

13.15

-0.33 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners74.08%
Inst Owner Change1.15%
Ins Owners0.73%
Ins Owner Change-0.55%
Market Cap503.38M
Revenue(TTM)25.42M
Net Income(TTM)-143.75M
Analysts86.15
Price Target20.4 (55.13%)
Short Float %2.83%
Short Ratio4.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.65%
Min EPS beat(2)-10.55%
Max EPS beat(2)19.86%
EPS beat(4)2
Avg EPS beat(4)9.2%
Min EPS beat(4)-20.31%
Max EPS beat(4)47.81%
EPS beat(8)6
Avg EPS beat(8)169.29%
EPS beat(12)7
Avg EPS beat(12)115.74%
EPS beat(16)8
Avg EPS beat(16)86.78%
Revenue beat(2)0
Avg Revenue beat(2)-88.39%
Min Revenue beat(2)-88.45%
Max Revenue beat(2)-88.33%
Revenue beat(4)1
Avg Revenue beat(4)-39.7%
Min Revenue beat(4)-88.45%
Max Revenue beat(4)98.17%
Revenue beat(8)5
Avg Revenue beat(8)58.11%
Revenue beat(12)8
Avg Revenue beat(12)73.98%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.11%
PT rev (3m)21.21%
EPS NQ rev (1m)1.01%
EPS NQ rev (3m)-1.98%
EPS NY rev (1m)7.65%
EPS NY rev (3m)6.24%
Revenue NQ rev (1m)-71.22%
Revenue NQ rev (3m)-81.45%
Revenue NY rev (1m)-7.53%
Revenue NY rev (3m)3.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.8
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-3.46
EYN/A
EPS(NY)-3.95
Fwd EYN/A
FCF(TTM)-3.38
FCFYN/A
OCF(TTM)-3.36
OCFYN/A
SpS0.66
BVpS8
TBVpS8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.09%
ROE -46.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.02%
ROA(5y)-16.26%
ROE(3y)-11.47%
ROE(5y)-19.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.42%
Cap/Sales 4.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.53
Quick Ratio 12.53
Altman-Z 2.81
F-Score3
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)102.24%
Cap/Depr(5y)173.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-281.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3233.33%
EPS Next Y-14.21%
EPS Next 2Y-5.45%
EPS Next 3Y-0.93%
EPS Next 5Y6.49%
Revenue 1Y (TTM)-87.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-96.53%
Revenue Next Year14.56%
Revenue Next 2Y31.43%
Revenue Next 3Y29.85%
Revenue Next 5Y46.56%
EBIT growth 1Y-441.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.21%
EBIT Next 3Y-28.1%
EBIT Next 5YN/A
FCF growth 1Y-189.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-209.24%
OCF growth 3YN/A
OCF growth 5YN/A

ENTRADA THERAPEUTICS INC / TRDA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ENTRADA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRDA.


What is the valuation status for TRDA stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTRADA THERAPEUTICS INC (TRDA). This can be considered as Overvalued.


What is the profitability of TRDA stock?

ENTRADA THERAPEUTICS INC (TRDA) has a profitability rating of 1 / 10.


Can you provide the financial health for TRDA stock?

The financial health rating of ENTRADA THERAPEUTICS INC (TRDA) is 8 / 10.


What is the earnings growth outlook for ENTRADA THERAPEUTICS INC?

The Earnings per Share (EPS) of ENTRADA THERAPEUTICS INC (TRDA) is expected to decline by -14.21% in the next year.